Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-24-000865
Filing Date
2024-05-15
Accepted
2024-05-15 16:03:21
Documents
65
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrkr-20240331x10q.htm   iXBRL 10-Q 930699
2 EX-31.1 mrkr-20240331xex31d1.htm EX-31.1 13536
3 EX-31.2 mrkr-20240331xex31d2.htm EX-31.2 13521
4 EX-32.1 mrkr-20240331xex32d1.htm EX-32.1 6864
5 EX-32.2 mrkr-20240331xex32d2.htm EX-32.2 7041
6 GRAPHIC mrkr-20240331x10q001.jpg GRAPHIC 12637
7 GRAPHIC mrkr-20240331x10q002.jpg GRAPHIC 46872
8 GRAPHIC mrkr-20240331x10q003.jpg GRAPHIC 35002
  Complete submission text file 0001410578-24-000865.txt   4696063

Data Files

Seq Description Document Type Size
9 EX-101.SCH mrkr-20240331.xsd EX-101.SCH 38506
10 EX-101.CAL mrkr-20240331_cal.xml EX-101.CAL 33765
11 EX-101.DEF mrkr-20240331_def.xml EX-101.DEF 172678
12 EX-101.LAB mrkr-20240331_lab.xml EX-101.LAB 310882
13 EX-101.PRE mrkr-20240331_pre.xml EX-101.PRE 265970
69 EXTRACTED XBRL INSTANCE DOCUMENT mrkr-20240331x10q_htm.xml XML 567144
Mailing Address 4551 KENNEDY COMMERCE DR. HOUSTON TX 77032
Business Address 4551 KENNEDY COMMERCE DR. HOUSTON TX 77032 (713) 400-6400
Marker Therapeutics, Inc. (Filer) CIK: 0001094038 (see all company filings)

EIN.: 880277072 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37939 | Film No.: 24950225
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)